Navigation Links
Generex Touts Pipeline Potential of Antigen Express Subsidiary
Date:2/7/2013

platform.  This technology enhances delivery of key target proteins like HER2 for cancer to a critical immune recognition site enhancing immune recognition. The Company has also developed compounds designed for important non-HER2 cancer associated protein targets using the Ii-Key technology platform. These include the melanoma-associated gp100 target, as well as cervical and head-and-neck cancers associated with Human Papilloma Virus (HPV). These compounds have shown significant activity in animal models that has been described in peer-reviewed publications.

In addition to cancer protein targets, the Company has clinically tested Ii-Key-based proteins designed to protect against the potentially pandemic influenza strains H5N1 (avian flu) and H1N1 (swine flu). The advantage here is that the Antigen vaccine technology is entirely synthetic, making it simple to manufacture. In the event of a potentially pandemic influenza virus, there is clearly a need for this type of flexible vaccine technology that can be brought into production rapidly.

The distinguishing feature of Antigen Express technology (Ii-Key) is the ability to activate critical components of the immune system (CD4+ T helper cells) in a robust and specific manner. Currently this is a unique technology platform that directs proteins to a critical immune component to be able to create specific immune stimulation. This Ii-Key technology is proprietary to Antigen Express. Consequently, the Company is in a good position to license the technology for combination with multiple different target proteins to create novel vaccine applications that may be of interest to other researchers and companies.

About Generex Biotechnology Corporation

Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavit
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Generex Announces Presentations of Antigen Express AE37 Breast Cancer Vaccine Data at ASCO 2012
2. Generex Announces New Members of Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine
3. Generex Augments Antigen Express Scientific Advisory Board
4. Generex Reports on Inaugural AE37 Breast Cancer Vaccine Scientific Advisory Board Meeting
5. Generex Announces OncUView.tv Interviews Featuring the Antigen Express AE37 Breast Cancer Vaccine at ASCO 2012
6. Generex Announces Results of Annual Stockholders Meeting
7. Generex Addresses Recent Trading Volume in Shares of its Common Stock
8. Generex Announces Details of Investor Conference Call
9. Generex Provides an Overview of its Cancer Immunotherapy Product, AE37, and Potential in Early Breast Cancer Given Current and Potential Future Therapies
10. Generex Points to Potential of Antigen Express Technology Platform beyond Its AE37 Breast Cancer Vaccine
11. Lilly Sets Date for Lilly Diabetes Pipeline Update to the Investment Community
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... CLEVELAND , Jan. 14, 2014 NineSigma ... will hold its Innovation Leadership Summit , May ... in Cleveland Ohio . ... innovators and organizations committed to breakthrough achievements through open ...
(Date:1/14/2014)... New York , January 14, 2014 ... Closed System Transfer Devices (CSTD) for hazardous drugs, today announced ... for the fourth straight year.   ... for pharmacy technicians, pharmacists, nurses and other medical ...
(Date:1/14/2014)... Spark Therapeutics , a late-stage gene therapy company, has ... a Phase 3 study for inherited retinal dystrophies caused by mutations ... Marrazzo , is presenting this and other corporate updates today, at ... Francisco . Marrazzo said Spark was able to achieve its ...
Breaking Medicine Technology:Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 4Equashield's Sales Grow by 60% in 2013 2Spark Therapeutics Achieves Recruitment Goal in Phase 3 Gene Therapy Clinical Study for Inherited Blindness 2Spark Therapeutics Achieves Recruitment Goal in Phase 3 Gene Therapy Clinical Study for Inherited Blindness 3
... 9, 2011   Endo Pharmaceuticals (Nasdaq: ENDP ) today ... Conference on Tuesday, March 15, 2011 at 3:45 p.m. ET.  Dr. ... the company,s products and development programs. The presentation will ... www.endo.com under the investors section.   ...
... Accumetrics, Inc., a privately-held developer and marketer ... easy-to-use point-of-care system for measuring platelet reactivity to ... were recently published in The Annals of ... platelet reactivity as a new recommendation for preoperative ...
Cached Medicine Technology:2011 Surgical Guidelines Recommend Point-of-Care Platelet Reactivity Testing Prior to Surgery 22011 Surgical Guidelines Recommend Point-of-Care Platelet Reactivity Testing Prior to Surgery 3
(Date:4/24/2014)... prescription opioid overdose deaths was outlined yesterday in the ... of agencies in the U.S. Department of Health and ... providers to expand their use of medications to treat ... number of misperceptions that have limited access to these ... can be used in combination with behavior therapies to ...
(Date:4/24/2014)... An Oregon State University researcher has found a ... the symptoms of autism spectrum disorder in very young ... the first to show a direct relationship between motor ... and gross motor skills should be included in treatment ... an assistant professor in OSU,s College of Public Health ...
(Date:4/23/2014)... frozen stool from healthy, unrelated donors was safe ... diarrhea caused by Clostridium difficile , according ... Clinical Infectious Diseases and available online. Known ... effective whether given via a colonoscope or a ... make this promising treatment more readily available to ...
(Date:4/23/2014)... A Michigan State University researcher is looking to give ... workout, and her latest research shows that a cyber ... the Games for Health Journal , is the ... still a better motivator during exercise, a software-generated partner ... that something that isn,t real can still motivate people ...
(Date:4/23/2014)... that targets an important brain receptor has a dramatic ... relapse behavior, a University at Buffalo animal study has ... may be a novel lead compound for treating cocaine ... research was published as an online preview article in ... the compound, RO5263397, severely blunted a broad range of ...
Breaking Medicine News(10 mins):Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 2Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 3Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 4Health News:Motor skill deficiencies linked to autism severity in new research 2Health News:Pilot study suggests ways to widen access to fecal transplants for C. diff infections 2Health News:Cyber buddy is better than 'no buddy' 2Health News:Novel compound halts cocaine addiction and relapse behaviors 2
... Roxane Laboratories, Inc.,announced today the approval of ... Capsules, 1.25mg, 2.5mg, 5mg and 10mg by ... 2.5mg, 5mg and 10mg strengths will be,available ... are available for immediate shipment to wholesalers ...
... unsure of source; New York City links 7 infections ... -- The number of people known to have fallen ... 383 in 30 states plus the District of Columbia, ... increase is not due to new infections but mainly ...
... continues monitoring and evaluating wrong-site surgeries,with the ... surgery,update, HARRISBURG, Pa., June 18 ... Time Out Day," which is a,national effort ... out" before every,operation to confirm correct patient, ...
... Kevin Max, Ken,Andrews, Joanne Cash and others, ... compilation CD with proceeds benefiting Suicide Awareness Voices ... June 24, 2008. The,release features an exclusive mix ... Kevin Herchen and Max Schnitzer and selections from,Charlotte ...
... DC, June 2008 -- Research findings and innovative approaches ... for cures for adults living with type 1 diabetes, ... (JDRF,s) Global Research Forum in Washington D.C. , Type ... the destruction of insulin-producing beta cells in the pancreas. ...
... irregular heartbeat combine, study finds , , WEDNESDAY, June 18 ... irregular heartbeat called atrial fibrillation can form a deadly ... a less onerous strategy called "rate control" may be ... these circumstances. , "Our results show that one strategy ...
Cached Medicine News:Health News:Roxane Laboratories, Inc. Announces the Launch of Ramipril Capsules 2Health News:Tainted Tomato Cases Jump to 383 People in 30 states, D.C. 2Health News:Tainted Tomato Cases Jump to 383 People in 30 states, D.C. 3Health News:Patient Safety Authority Supports 'National Time Out Day' 2Health News:'Hope, Volume One,' a CD benefiting Suicide Awareness Voices of Education (SAVE), to Be released on June 24, 2008 2Health News:Science, hope for adults with type 1 diabetes focus of JDRF's Annual Global Diabetes Research Forum 2Health News:Science, hope for adults with type 1 diabetes focus of JDRF's Annual Global Diabetes Research Forum 3Health News:Cardiologists Spot Best Treatment for a Deadly Duo 2Health News:Cardiologists Spot Best Treatment for a Deadly Duo 3
... Geometric Data Hemastainer. Formulated to ... quality control tested on human ... staining and absence of precipitate. ... a minimum of eight hours ...
... Unique molecular suspension in methanol ... blood, chromosome, and histology smears. Our ... that rapidly penetrates cellular elements producing ... nuclear detail and unexcelled brilliance in ...
Wright-Giemsa Stain Solutions...
... Stain is ideal for stat, routine or ... smears and bone marrow. Our unique manufacturing ... yield excellent color intensity and morphological differentiation. ... in the Wright's staining procedure and includes ...
Medicine Products: